Apyx Medical Corp Other Executive Compensation Disclosures
Every other executive-compensation XBRL fact the company filed (policies, award timing, footnotes, adjustments), newest first. Long text is shortened; the filing has the full text.
- 2023-06-23: Disclosure Named Executive Officers Footnote; Period 2022-01-01..2022-12-31; Value This section is included to comply with the provisions of Item 402(v) of Regulation S-K. For a more comprehensive analysis of our compensation philosophy please see the General Compensation Philosophy section of this filing. In the table and footnotes below, “PEO” refers to our principal executive o….
- 2023-06-23: Disclosure Pay versus Performance Table; Period 2022-01-01..2022-12-31; Value Pay versus performance table (a) (b) (c) (d) (e) (f) (h) Year Summary compensation table total for PEO Compensation actually paid to PEO Average summary compensation table total for non-PEO NEOs (1) Average compensation actually paid to non-PEO NEOs (1) Value of initial fixed $100 investment based o….
- 2023-06-23: Disclosure Adjustment To Non PEO NEO Compensation Footnote; Period 2022-01-01..2022-12-31; Value The following table summarizes the adjustments from summary table total compensation to compensation actually paid: PEO Non-PEO NEOs 2022 2021 2022 2021 Summary compensation table total compensation $ 2,170,236 $ 1,594,394 $ 974,614 $ 776,134 Grant date fair value of awards granted during the year (….
- 2023-06-23: Disclosure Adjustment To PEO Compensation Footnote; Period 2022-01-01..2022-12-31; Value The following table summarizes the adjustments from summary table total compensation to compensation actually paid: PEO Non-PEO NEOs 2022 2021 2022 2021 Summary compensation table total compensation $ 2,170,236 $ 1,594,394 $ 974,614 $ 776,134 Grant date fair value of awards granted during the year (….
| Filed | Disclosure | Qualifiers | Period | Value |
|---|---|---|---|---|
| 2023-06-23 DEF 14A | Named Executive Officers Footnote | 2022-01-01..2022-12-31 | This section is included to comply with the provisions of Item 402(v) of Regulation S-K. For a more comprehensive analysis of our compensation philosophy please see the General Compensation Philosophy section of this filing. In the table and footnotes below, “PEO” refers to our principal executive o… | |
| 2023-06-23 DEF 14A | Pay versus Performance Table | 2022-01-01..2022-12-31 | Pay versus performance table (a) (b) (c) (d) (e) (f) (h) Year Summary compensation table total for PEO Compensation actually paid to PEO Average summary compensation table total for non-PEO NEOs (1) Average compensation actually paid to non-PEO NEOs (1) Value of initial fixed $100 investment based o… | |
| 2023-06-23 DEF 14A | Adjustment To Non PEO NEO Compensation Footnote | 2022-01-01..2022-12-31 | The following table summarizes the adjustments from summary table total compensation to compensation actually paid: PEO Non-PEO NEOs 2022 2021 2022 2021 Summary compensation table total compensation $ 2,170,236 $ 1,594,394 $ 974,614 $ 776,134 Grant date fair value of awards granted during the year (… | |
| 2023-06-23 DEF 14A | Adjustment To PEO Compensation Footnote | 2022-01-01..2022-12-31 | The following table summarizes the adjustments from summary table total compensation to compensation actually paid: PEO Non-PEO NEOs 2022 2021 2022 2021 Summary compensation table total compensation $ 2,170,236 $ 1,594,394 $ 974,614 $ 776,134 Grant date fair value of awards granted during the year (… | |
| 2023-06-23 DEF 14A | Adjustment To Compensation | AdjToComp: EquityAwardsGrantedDuringTheYear; ExecutiveCategory: Peo | 2022-01-01..2022-12-31 | -$1.66M |
| 2023-06-23 DEF 14A | Adjustment To Compensation | AdjToComp: EquityAwardsGrantedDuringTheYear; ExecutiveCategory: Peo | 2021-01-01..2021-12-31 | -$701.42K |
| 2023-06-23 DEF 14A | Adjustment To Compensation | AdjToComp: EquityAwardsGrantedDuringTheYear; ExecutiveCategory: NonPeoNeo | 2022-01-01..2022-12-31 | -$612.02K |
| 2023-06-23 DEF 14A | Adjustment To Compensation | AdjToComp: EquityAwardsGrantedDuringTheYear; ExecutiveCategory: NonPeoNeo | 2021-01-01..2021-12-31 | -$257.86K |
| 2023-06-23 DEF 14A | Adjustment To Compensation | AdjToComp: EquityAwardsGrantedDuringTheYearOutstandingAndUnvested; ExecutiveCategory: Peo | 2022-01-01..2022-12-31 | $255.11K |
| 2023-06-23 DEF 14A | Adjustment To Compensation | AdjToComp: EquityAwardsGrantedDuringTheYearOutstandingAndUnvested; ExecutiveCategory: Peo | 2021-01-01..2021-12-31 | $1.00M |
| 2023-06-23 DEF 14A | Adjustment To Compensation | AdjToComp: EquityAwardsGrantedDuringTheYearOutstandingAndUnvested; ExecutiveCategory: NonPeoNeo | 2022-01-01..2022-12-31 | $93.79K |
| 2023-06-23 DEF 14A | Adjustment To Compensation | AdjToComp: EquityAwardsGrantedDuringTheYearOutstandingAndUnvested; ExecutiveCategory: NonPeoNeo | 2021-01-01..2021-12-31 | $368.13K |
| 2023-06-23 DEF 14A | Adjustment To Compensation | AdjToComp: EquityAwardsGrantedInPriorYearsOutstandingAndUnvested; ExecutiveCategory: Peo | 2022-01-01..2022-12-31 | -$1.16M |
| 2023-06-23 DEF 14A | Adjustment To Compensation | AdjToComp: EquityAwardsGrantedInPriorYearsOutstandingAndUnvested; ExecutiveCategory: Peo | 2021-01-01..2021-12-31 | $1.03M |
| 2023-06-23 DEF 14A | Adjustment To Compensation | AdjToComp: EquityAwardsGrantedInPriorYearsOutstandingAndUnvested; ExecutiveCategory: NonPeoNeo | 2022-01-01..2022-12-31 | -$425.08K |
| 2023-06-23 DEF 14A | Adjustment To Compensation | AdjToComp: EquityAwardsGrantedInPriorYearsOutstandingAndUnvested; ExecutiveCategory: NonPeoNeo | 2021-01-01..2021-12-31 | $356.31K |
| 2023-06-23 DEF 14A | Adjustment To Compensation | AdjToComp: EquityAwardsGrantedInPriorYearsVested; ExecutiveCategory: Peo | 2022-01-01..2022-12-31 | -$257.93K |
| 2023-06-23 DEF 14A | Adjustment To Compensation | AdjToComp: EquityAwardsGrantedInPriorYearsVested; ExecutiveCategory: Peo | 2021-01-01..2021-12-31 | $224.03K |
| 2023-06-23 DEF 14A | Adjustment To Compensation | AdjToComp: EquityAwardsGrantedInPriorYearsVested; ExecutiveCategory: NonPeoNeo | 2022-01-01..2022-12-31 | -$86.47K |
| 2023-06-23 DEF 14A | Adjustment To Compensation | AdjToComp: EquityAwardsGrantedInPriorYearsVested; ExecutiveCategory: NonPeoNeo | 2021-01-01..2021-12-31 | $140.61K |
| 2023-06-23 DEF 14A | Compensation Actually Paid Vs Net Income | 2022-01-01..2022-12-31 | The following table presents a comparison of our actual compensation paid to NEOs versus our total stockholder return, net losses and sales: (in thousands except per share data) 2022 2021 Change Total stockholder return (change in stock price) $ 2.34 $ 12.82 -81.7 % Net loss $ (23,184) $ (15,172) -5… | |
| 2023-06-23 DEF 14A | Compensation Actually Paid Vs Total Shareholder Return | 2022-01-01..2022-12-31 | The following table presents a comparison of our actual compensation paid to NEOs versus our total stockholder return, net losses and sales: (in thousands except per share data) 2022 2021 Change Total stockholder return (change in stock price) $ 2.34 $ 12.82 -81.7 % Net loss $ (23,184) $ (15,172) -5… |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Microbot Medical Inc. (MBOT) | $0.089B | -7.97 | |
| KORU Medical Systems, Inc. (KRMD) | United States | $0.151B | -106.78 |
| LENSAR, Inc. (LNSR) | United States | $0.087B | 2.02 |
| SkinHealth Systems Inc. (SKIN) | United States | $0.086B | -3.17 |
| Pulmonx Corp (LUNG) | United States | $0.082B | -1.16 |
| RenovoRx, Inc. (RNXT) | United States | $0.076B | -3.62 |
| FRACTYL HEALTH, INC. (GUTS) | United States | $0.075B | -1.18 |
| Lucid Diagnostics Inc. (LUCD) | United States | $0.170B | |
| CVRx, Inc. (CVRX) | United States | $0.067B | -2.62 |
| DarioHealth Corp. (DRIO) | $0.066B | -1.39 |